MX2010009623A - Derivados de 1-bencil-3-hidroximetilindazol novedosos y su uso en el tratamiento de enfermedades basadas en la expresion de mcp-1, cx3cr1 y p40. - Google Patents
Derivados de 1-bencil-3-hidroximetilindazol novedosos y su uso en el tratamiento de enfermedades basadas en la expresion de mcp-1, cx3cr1 y p40.Info
- Publication number
- MX2010009623A MX2010009623A MX2010009623A MX2010009623A MX2010009623A MX 2010009623 A MX2010009623 A MX 2010009623A MX 2010009623 A MX2010009623 A MX 2010009623A MX 2010009623 A MX2010009623 A MX 2010009623A MX 2010009623 A MX2010009623 A MX 2010009623A
- Authority
- MX
- Mexico
- Prior art keywords
- cx3cr1
- mcp
- benzyl
- expression
- diseases based
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
- 101100504320 Caenorhabditis elegans mcp-1 gene Proteins 0.000 title 1
- AKQDXNFPEFHRLS-UHFFFAOYSA-N (1-benzylindazol-3-yl)methanol Chemical class C12=CC=CC=C2C(CO)=NN1CC1=CC=CC=C1 AKQDXNFPEFHRLS-UHFFFAOYSA-N 0.000 abstract 2
- 102100021943 C-C motif chemokine 2 Human genes 0.000 abstract 2
- 101710155857 C-C motif chemokine 2 Proteins 0.000 abstract 2
- 108090000835 CX3C Chemokine Receptor 1 Proteins 0.000 abstract 2
- 102100039196 CX3C chemokine receptor 1 Human genes 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Virology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- AIDS & HIV (AREA)
- Transplantation (AREA)
- Child & Adolescent Psychology (AREA)
Abstract
La presente invención se refiere a nuevos derivados de 1-bencil-3-hidroximetilindazol de acuerdo con la Fórmula (I) descritos en las reivindicaciones, y a una composición farmacéutica que los comprende, junto con un vehículo farmacéuticamente aceptable. Además, la presente invención se refiere al uso de derivados de 1-bencil-3-hidroximetilindazol para la preparación de una composición farmacéutica que es activa en el tratamiento de enfermedades basadas en la expresión de MCP-1, CX3CR1 y p40, y a su uso en un método para tratar o prevenir enfermedades basadas en la expresión de MCP-1, CX3CR1 y p40.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08425139 | 2008-03-07 | ||
| PCT/EP2009/052585 WO2009109613A2 (en) | 2008-03-07 | 2009-03-05 | Novel 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1 and p40 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2010009623A true MX2010009623A (es) | 2010-09-28 |
Family
ID=39671487
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2010009623A MX2010009623A (es) | 2008-03-07 | 2009-03-05 | Derivados de 1-bencil-3-hidroximetilindazol novedosos y su uso en el tratamiento de enfermedades basadas en la expresion de mcp-1, cx3cr1 y p40. |
| MX2010009626A MX2010009626A (es) | 2008-03-07 | 2009-03-05 | Derivados de 1-bencil-3-hidroximetilindazol y su uso en el tratamiento de enfermedades basadas en la expresion de mcp-1, cx3cr1. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2010009626A MX2010009626A (es) | 2008-03-07 | 2009-03-05 | Derivados de 1-bencil-3-hidroximetilindazol y su uso en el tratamiento de enfermedades basadas en la expresion de mcp-1, cx3cr1. |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US7919518B2 (es) |
| EP (3) | EP2254869B1 (es) |
| JP (2) | JP5509101B2 (es) |
| KR (2) | KR101599867B1 (es) |
| CN (2) | CN101945855B (es) |
| AR (2) | AR070811A1 (es) |
| AU (2) | AU2009221083B2 (es) |
| BR (2) | BRPI0907977A2 (es) |
| CA (2) | CA2712403C (es) |
| CY (2) | CY1117584T1 (es) |
| DK (2) | DK2254870T3 (es) |
| EA (2) | EA018241B1 (es) |
| ES (2) | ES2637009T3 (es) |
| GE (2) | GEP20135983B (es) |
| HR (2) | HRP20171208T1 (es) |
| HU (1) | HUE027098T2 (es) |
| IL (3) | IL206893A0 (es) |
| LT (1) | LT2254869T (es) |
| MX (2) | MX2010009623A (es) |
| PL (2) | PL2254870T3 (es) |
| PT (1) | PT2254869T (es) |
| SG (1) | SG188177A1 (es) |
| SI (2) | SI2254870T1 (es) |
| UA (2) | UA103605C2 (es) |
| WO (2) | WO2009109618A2 (es) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE047318T2 (hu) * | 2008-03-07 | 2020-04-28 | Acraf | 1-benzil-3-hidroximetilindazol származékok és alkalmazásuk az MCP-1, CX3CR1 és P40 expresszióján alapuló betegségek kezelésében |
| AU2009221083B2 (en) * | 2008-03-07 | 2013-11-28 | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. | Novel 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of MCP-1, CX3CR1 and p40 |
| SI2262777T1 (sl) | 2008-03-07 | 2016-05-31 | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. | 1-benzil-3-hidroksimetilindazolni derivati in njihova uporaba pri zdravljenju bolezni, ki temeljijo na ekspresiji MCP-1 in CX3CR1 |
| BR112012002130A2 (pt) | 2009-08-03 | 2015-09-15 | Aziende Chimique Riunite Angelini Francesco A C R A F S P A | processo para a preparação de composto,e, composto intermediário |
| UA108742C2 (uk) * | 2009-09-23 | 2015-06-10 | Фармацевтична композиція для лікування запальних захворювань, опосередкованих mcp-1 | |
| CN104334173B (zh) * | 2012-05-01 | 2017-05-03 | 特兰斯拉图姆医学公司 | 用于治疗和诊断致盲性眼病的方法 |
| US8999292B2 (en) | 2012-05-01 | 2015-04-07 | Translatum Medicus Inc. | Methods for treating and diagnosing blinding eye diseases |
| JP6257596B2 (ja) * | 2012-05-18 | 2018-01-10 | サノフイ | ピラゾール誘導体およびｌｐａｒ５アンタゴニストとしてのその使用 |
| JP2015521183A (ja) | 2012-05-18 | 2015-07-27 | サノフイ | ピリジン誘導体および病理学的血栓形成に関連する状態の治療へのその使用 |
| AU2013342209B2 (en) | 2012-11-09 | 2016-05-26 | Colgate-Palmolive Company | Block copolymers for tooth enamel protection |
| US20170079955A1 (en) * | 2014-05-15 | 2017-03-23 | Shelley Romayne Boyd | Compositions and methods for treating and diagnosing ocular disorders |
| CA2988983A1 (en) * | 2015-06-12 | 2016-12-15 | Vettore, LLC | Mct4 inhibitors for treating disease |
| CA2989270A1 (en) * | 2015-06-16 | 2016-12-22 | Translatum Medicus, Inc. | Compositions and methods for treating and diagnosing ocular disorders |
| JP7123929B2 (ja) | 2016-12-12 | 2022-08-23 | ベットーレ リミテッド ライアビリティー カンパニー | Ｍｃｔ４の複素環阻害剤 |
| GB201811169D0 (en) | 2018-07-06 | 2018-08-29 | Kancera Ab | New compounds |
| JP6612004B1 (ja) * | 2018-07-31 | 2019-11-27 | 株式会社親広産業 | グルコース消費促進剤および解糖系促進剤 |
| WO2020026471A1 (ja) * | 2018-07-31 | 2020-02-06 | 株式会社親広産業 | グルコース消費促進剤および解糖系促進剤 |
| EP3990433A4 (en) * | 2019-06-25 | 2023-07-26 | Translatum Medicus Inc. | METHODS FOR THE MANUFACTURE OF 2-((1-BENZYL-1H-INDAZOL-3-YL)METHOXY)-2-METHYLPROPANOIC ACID AND ITS DERIVATIVES |
| CN113929627A (zh) * | 2021-10-19 | 2022-01-14 | 吕梁学院 | 一种宾达利的合成方法 |
| WO2024108386A1 (zh) * | 2022-11-22 | 2024-05-30 | 中国科学院深圳先进技术研究院 | 抗mcp1中和抗体在制备治疗神经退行性疾病引起的系统性炎症药物中的应用 |
| WO2024165925A1 (en) * | 2023-02-10 | 2024-08-15 | Translatum Medicus Inc. | Bindarit conjugates, compositions and methods for treating ocular diseases or disorders |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US364371A (en) * | 1887-06-07 | peice | ||
| US416359A (en) * | 1889-12-03 | Sash-fastener | ||
| IT1230441B (it) * | 1989-02-07 | 1991-10-23 | Acraf | Eteri della serie dell'indazolo |
| IT1253703B (it) | 1991-04-22 | 1995-08-23 | Angelini Francesco Ist Ricerca | Uso di acidi metossi alcanoici dell'indazolo per preparare un farmaco attivo nel trattamento di malattie autoimmunitarie |
| IT1293795B1 (it) * | 1997-07-28 | 1999-03-10 | Angelini Ricerche Spa | Farmaco attivo nel ridurre la produzione di proteina mcp-1 |
| EP1185528A4 (en) | 1999-06-17 | 2003-03-26 | Shionogi Biores Corp | INHIBITORS OF IL-12 PRODUCTION |
| EP1188438A1 (en) | 2000-09-15 | 2002-03-20 | Warner-Lambert Company | Pharmaceutical composition for preventing or treating a disease associated with an excess of Il-12 production |
| EP1199074A1 (en) | 2000-09-15 | 2002-04-24 | Warner-Lambert Company | Pharmaceutical composition for preventing or treating a disease associated with an excess of il-12 production |
| CA2440744C (en) | 2001-03-15 | 2009-12-08 | Seikagaku Corporation | Il-12 expression controlling agent |
| AU2002357033B2 (en) | 2001-11-30 | 2009-05-07 | Synta Pharmaceuticals Corporation | Pyrimidine compounds |
| JP2007507494A (ja) | 2003-10-07 | 2007-03-29 | アストラゼネカ・アクチエボラーグ | ケモカイン受容体アンタゴニストとりわけＣＸ３ＣＲ１として有用な新規な２−置換４−アミノ−チアゾロ［４，５−ｄ］ピリミジン |
| US8518401B1 (en) * | 2004-10-29 | 2013-08-27 | Eisai R&D Management Co., Ltd. | Treating inflammatory diseases with antibodies that inhibit fractalkine-CXCR1 interaction |
| TW200628159A (en) | 2004-11-10 | 2006-08-16 | Synta Pharmaceuticals Corp | IL-12 modulatory compounds |
| EP1827447A1 (en) | 2004-11-19 | 2007-09-05 | Synta Pharmaceuticals Corporation | Pyrimidine compounds and uses thereof |
| AR053347A1 (es) | 2005-04-06 | 2007-05-02 | Astrazeneca Ab | Derivados de [1,3]tiazolo[4,5-d]pirimidin-2(3h)-ona 5,7-sustituidos |
| UA90707C2 (en) | 2005-04-06 | 2010-05-25 | Астразенека Аб | Novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives |
| HUE047318T2 (hu) * | 2008-03-07 | 2020-04-28 | Acraf | 1-benzil-3-hidroximetilindazol származékok és alkalmazásuk az MCP-1, CX3CR1 és P40 expresszióján alapuló betegségek kezelésében |
| SI2262777T1 (sl) * | 2008-03-07 | 2016-05-31 | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. | 1-benzil-3-hidroksimetilindazolni derivati in njihova uporaba pri zdravljenju bolezni, ki temeljijo na ekspresiji MCP-1 in CX3CR1 |
| AU2009221083B2 (en) * | 2008-03-07 | 2013-11-28 | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. | Novel 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of MCP-1, CX3CR1 and p40 |
-
2009
- 2009-03-05 AU AU2009221083A patent/AU2009221083B2/en not_active Ceased
- 2009-03-05 EA EA201071038A patent/EA018241B1/ru not_active IP Right Cessation
- 2009-03-05 EP EP09717638.2A patent/EP2254869B1/en active Active
- 2009-03-05 GE GEAP200911963A patent/GEP20135983B/en unknown
- 2009-03-05 US US12/864,767 patent/US7919518B2/en not_active Expired - Fee Related
- 2009-03-05 JP JP2010549146A patent/JP5509101B2/ja active Active
- 2009-03-05 PL PL09718467T patent/PL2254870T3/pl unknown
- 2009-03-05 ES ES09717638.2T patent/ES2637009T3/es active Active
- 2009-03-05 EP EP17153930.7A patent/EP3181551A1/en not_active Withdrawn
- 2009-03-05 EA EA201071040A patent/EA019711B1/ru not_active IP Right Cessation
- 2009-03-05 HU HUE09718467A patent/HUE027098T2/en unknown
- 2009-03-05 MX MX2010009623A patent/MX2010009623A/es active IP Right Grant
- 2009-03-05 SI SI200931404A patent/SI2254870T1/sl unknown
- 2009-03-05 DK DK09718467.5T patent/DK2254870T3/en active
- 2009-03-05 SI SI200931705T patent/SI2254869T1/sl unknown
- 2009-03-05 HR HRP20171208TT patent/HRP20171208T1/hr unknown
- 2009-03-05 MX MX2010009626A patent/MX2010009626A/es active IP Right Grant
- 2009-03-05 BR BRPI0907977-7A patent/BRPI0907977A2/pt not_active IP Right Cessation
- 2009-03-05 CA CA2712403A patent/CA2712403C/en not_active Expired - Fee Related
- 2009-03-05 KR KR1020107017445A patent/KR101599867B1/ko not_active Expired - Fee Related
- 2009-03-05 EP EP09718467.5A patent/EP2254870B1/en active Active
- 2009-03-05 HR HRP20160462TT patent/HRP20160462T1/hr unknown
- 2009-03-05 LT LTEP09717638.2T patent/LT2254869T/lt unknown
- 2009-03-05 CA CA2712703A patent/CA2712703C/en not_active Expired - Fee Related
- 2009-03-05 CN CN200980105073.4A patent/CN101945855B/zh not_active Expired - Fee Related
- 2009-03-05 KR KR1020107017806A patent/KR101581828B1/ko not_active Expired - Fee Related
- 2009-03-05 ES ES09718467.5T patent/ES2569330T3/es active Active
- 2009-03-05 PT PT97176382T patent/PT2254869T/pt unknown
- 2009-03-05 JP JP2010549143A patent/JP5509099B2/ja active Active
- 2009-03-05 SG SG2013013123A patent/SG188177A1/en unknown
- 2009-03-05 WO PCT/EP2009/052590 patent/WO2009109618A2/en not_active Ceased
- 2009-03-05 GE GEAP200911965A patent/GEP20135912B/en unknown
- 2009-03-05 CN CN200980105556.4A patent/CN101952256B/zh not_active Expired - Fee Related
- 2009-03-05 BR BRPI0907976-9A patent/BRPI0907976A2/pt not_active IP Right Cessation
- 2009-03-05 WO PCT/EP2009/052585 patent/WO2009109613A2/en not_active Ceased
- 2009-03-05 DK DK09717638.2T patent/DK2254869T3/en active
- 2009-03-05 AU AU2009221089A patent/AU2009221089B2/en not_active Ceased
- 2009-03-05 US US12/865,923 patent/US8835481B2/en not_active Expired - Fee Related
- 2009-03-05 PL PL09717638T patent/PL2254869T3/pl unknown
- 2009-03-06 AR ARP090100801A patent/AR070811A1/es unknown
- 2009-03-06 AR ARP090100800A patent/AR070810A1/es unknown
- 2009-05-03 UA UAA201008883A patent/UA103605C2/uk unknown
- 2009-05-03 UA UAA201008570A patent/UA105170C2/uk unknown
-
2010
- 2010-07-08 IL IL206893A patent/IL206893A0/en not_active IP Right Cessation
- 2010-07-21 IL IL207131A patent/IL207131A/en not_active IP Right Cessation
-
2011
- 2011-03-07 US US13/041,557 patent/US8283348B2/en not_active Expired - Fee Related
- 2011-10-06 IL IL215579A patent/IL215579A/en not_active IP Right Cessation
-
2016
- 2016-05-13 CY CY20161100406T patent/CY1117584T1/el unknown
-
2017
- 2017-08-09 CY CY20171100858T patent/CY1119252T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2010009623A (es) | Derivados de 1-bencil-3-hidroximetilindazol novedosos y su uso en el tratamiento de enfermedades basadas en la expresion de mcp-1, cx3cr1 y p40. | |
| MX2010009625A (es) | Derivados de 1-bencil-3-hidroximetilindazol y uso de los mismos en el tratamiento de enfermedades basadas en la expresion de mcp-1, cx3cr1 y p40. | |
| MX2010009624A (es) | Derivados de 1-bencil-3-hidroximetilindazol y uso de los mismos en el tratamiento de enfermedades basadas en la expresion de mcp-1 y cx3cr1. | |
| EP2512479A4 (en) | METHOD AND COMPOSITIONS FOR TREATING PERIPHERAL VASCULAR DISEASE | |
| UA98961C2 (uk) | Похідні піразинону та їх застосування у лікуванні легеневих захворювань | |
| WO2015157559A3 (en) | 10',11'-modified saxitoxins useful for the treatment of pain | |
| WO2011107608A8 (en) | Heterocyclic amides as rock inhibitors | |
| MY147994A (en) | Azabiphenylaminobenzoic acid derivatives as dhodh inhibitors | |
| MD20150035A2 (ro) | Inhibitori de tirozinkinaza Bruton | |
| EA201270221A1 (ru) | Лечение болезни крона с применением лаквинимода | |
| MY164731A (en) | Compound | |
| MX2010002392A (es) | Composiciones de brimonidina mejoradas para tratar eritema. | |
| WO2011127333A3 (en) | Compounds for treating disease, for administering, and for pharmaceutical compositions | |
| MX2011006006A (es) | Compuestos, composicion farmaceutica y metodos para utilizarse en el tratamiento de trastornos metabolicos. | |
| MX2009010407A (es) | Derivados fluorados de deferiprona. | |
| MX2012000954A (es) | Composicion far,aceutica topica que incuye la rel-n-[6-[(2r,6s)-2,6-dimetil-4-morfolinil]-3-piridinil]-2-metil- 4'-(trifluoro-metoxi)-[1,1'-bifenil]-3-carboxamida. | |
| MX2013002208A (es) | Derivados de sulfonilpiperazina que interactuan con la proteina reguladora de glucocinasa para el tratamiento de diabetes. | |
| SG10201809506TA (en) | Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions | |
| TW200640465A (en) | New pharmaceutically active compounds for the treatment of respiratory diseases | |
| MX2010008586A (es) | Amidas de acido 3-(4-fluorofenil)-3-hidroxi-2-amino-propionico y compuestos relacionados que tienen actividad analgesica. | |
| AU2016219606A1 (en) | Pharmaceutical composition for treating or preventing burn injuries | |
| HK1148271B (en) | 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1 and cx3cr1 | |
| HK1146045A (en) | 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cxcr1 and p40 | |
| PL1904511T3 (pl) | Homogemcytabiny | |
| UA60688U (ru) | Фармацевтическая композиция для лечения заболеваний органов дыхания и заболеваний аллергического типа |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |